Premium
Debrisoquin, a selective inhibitor of intraneuronal monoamine oxidase in man
Author(s) -
Pettinger W. A.,
Korn A.,
Spiegel H.,
Solomon H. M.,
Pocelinko R.,
Abrams W. B.
Publication year - 1969
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt1969105667
Subject(s) - tyramine , tryptamine , monoamine oxidase , chemistry , norepinephrine , monoamine oxidase inhibitor , endocrinology , excretion , medicine , urinary system , pharmacology , enzyme , dopamine , biochemistry
Indices of MAO activity were monitored during administration of debrisoquin to 4 patients with hypertension. That there was no inhibition of MAO was indicated by unaltered urinary tryptamine and tyramine excretion, no depression of intestinal mucosal MAO activity, and no decrease of intestinal inactivation of orally ingested tyramine. Inhibition of sympathetic neuronal MAO is suggested by increased sensitivity to intravenous tyramine with a slight increase in norepinephrine sensitivity, decreased urinary VMA, and increased NMN excretion. It is suggested that anatomic selectivity of enzyme inhibition is related to drug‐concentrating mechanisms in sympathetic neurons.